By engaging receptors such as GPR41/43 and aryl hydrocarbon receptor (AhR) or altering epigenetic programs through histone deacetylase (HDAC) inhibition, these metabolites remodel immune niches both locally and at distant tumor sites [25, 26]. Here, AHR is linked to neoplasm.